A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in patients (pts) with advanced solid tumors.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. TPS2609-TPS2609
Author(s):  
Anthony J. Olszanski ◽  
Mark R. Middleton ◽  
Rastilav Bahleda ◽  
Rebecca Suk Heist ◽  
Lakshmi Rangachari ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Kinase Inhibitor ◽  
Advanced Solid Tumors ◽  
Aurora A Kinase ◽  
Aurora A ◽  
Phase Ib ◽  
Raf Kinase

A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e13026-e13026 ◽  
Author(s):  
S. E. Minton ◽  
P. LoRusso ◽  
A. C. Lockhart ◽  
M. Saif ◽  
S. S. Krishnamurthi ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Kinase Inhibitor ◽  
Advanced Solid Tumors ◽  
Aurora A Kinase ◽  
Aurora A

Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors

2019 ◽  
Vol 42 (5) ◽  
pp. 413-420 ◽  
Author(s):  
Hiral A. Shah ◽  
James H. Fischer ◽  
Neeta K. Venepalli ◽  
Oana C. Danciu ◽  
Sonia Christian ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Kinase Inhibitor ◽  
Advanced Solid Tumors ◽  
Aurora A Kinase ◽  
Aurora A ◽  
Vegfr Inhibitor

Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors

2015 ◽  
Vol 53 (07) ◽  
pp. 563-572 ◽  
Author(s):  
Gerald S. Falchook ◽  
Karthik Venkatakrishnan ◽  
John Sarantopoulos ◽  
Razelle Kurzrock ◽  
Alain C. Mita ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Kinase Inhibitor ◽  
Relative Bioavailability ◽  
Oral Solution ◽  
Advanced Solid Tumors ◽  
Aurora A Kinase ◽  
Aurora A

Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors

2018 ◽  
Vol 37 (4) ◽  
pp. 666-673 ◽  
Author(s):  
Xiaofei Zhou ◽  
Sandeepraj Pusalkar ◽  
Swapan K. Chowdhury ◽  
Shawn Searle ◽  
Yuexian Li ◽  
...  
Keyword(s):  
Mass Balance ◽  
Solid Tumors ◽  
Kinase Inhibitor ◽  
Advanced Solid Tumors ◽  
Aurora A Kinase ◽  
Aurora A

scholarly journals Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors

Drugs in R&D ◽  
2015 ◽  
Vol 16 (1) ◽  
pp. 45-52 ◽  
Author(s):  
Gerald S. Falchook ◽  
Xiaofei Zhou ◽  
Karthik Venkatakrishnan ◽  
Razelle Kurzrock ◽  
Devalingam Mahalingam ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Kinase Inhibitor ◽  
Advanced Solid Tumors ◽  
Aurora A Kinase ◽  
Aurora A ◽  
Effect Of Food

scholarly journals Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

2012 ◽  
Vol 18 (17) ◽  
pp. 4764-4774 ◽  
Author(s):  
Andres Cervantes ◽  
Elena Elez ◽  
Desamparados Roda ◽  
Jeffrey Ecsedy ◽  
Teresa Macarulla ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Kinase Inhibitor ◽  
Advanced Solid Tumors ◽  
Aurora A Kinase ◽  
Aurora A ◽  
Pharmacodynamic Study
Sign in / Sign up

Export Citation Format

Share Document